Add like
Add dislike
Add to saved papers

Respiratory-Triggered Flow-Independent Noncontrast Non-ECG-Gated MRV (REACT) Versus Contrast-Enhanced MRV for Central Venous Evaluation in Children and Young Adults: A Six-Reader Study.

Background: Contrast-enhanced MRI is commonly used to evaluate thoracic central venous patency in children and young adults. A flow-independent, noncontrast non-ECG-gated 3D MR angiography-MR venography (MRV) technique described in 2019 ["relaxation-enhanced angiography without contrast and triggering" (REACT)] may facilitate such evaluation. Objective: To compare image quality, diagnostic confidence, and interreader agreement between respiratory-triggered REACT and 3D Dixon-based contrast-enhanced MRV (CE-MRV) for evaluating thoracic central venous patency in children and young adults. Methods: This retrospective study included 42 consecutive children and young adults who underwent MRI of the neck and chest to evaluate central venous patency between August 2019 and January 2021 (median age, 5.2 years; IQR: 1.4-15.1 years; 22 female, 20 male). Examinations included respiratory-triggered REACT and navigator-gated CE-MRV sequences, based on the institution's standard-of-care protocol. Six pediatric radiologists from four different institutions independently reviewed REACT and CE-MRV sequences, assessing overall image quality (1-5; 5=excellent), diagnostic confidence (1-5; 5=extremely confident), and presence of clinically relevant artifact(s). Readers classified seven major central vessels as normal or abnormal (e.g., narrowing, thrombosis, or occlusion). Analysis used Wilcoxon signed-rank and McNemar tests, and Fleiss' kappa coefficients. Results: Distribution of overall image quality scores was higher (p=.02) for REACT than for CE-MRV for one reader (both sequences: median score, 5). Image quality was not significantly different between sequences for the remaining five readers (all p>.05). Diagnostic confidence and frequency of clinically relevant artifact(s) were not significantly different between sequences for any reader (all p>.05). Interreader agreement for vessel classification (normal vs abnormal) was similar between sequences for all seven vessels (REACT, κ=0.37-0.81; CE-MRV, κ=0.34-0.81). Pooling readers and vessels, 65.4% of vessels were normal by both sequences, 18.7% abnormal by both sequences. 9.8% abnormal by REACT only, and 6.1% abnormal by CE-MRV only. Conclusion: Respiratory-triggered REACT, in comparison with CE-MRV, demonstrated no significant difference in image quality (aside from for one of six readers), diagnostic confidence, or frequency of artifact(s), with similar interreader agreement for vessel classification as normal or abnormal. Clinical Impact: High-resolution 3D MR venography performed without IV contrast material can be used to assess central venous patency in children and young adults.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app